TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Atazanavir/Ritonavir Maintenance Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* On first antiretroviral regimen, including at least 2 NRTIs and 1 PI, for at least 48 weeks immediately prior to study entry~* CD4 count of 250 cells/mm3 or greater~* Viral load less than 50 copies/ml within 30 days prior to entry~* Willing to use acceptable methods of contraception~Exclusion Criteria:~* Current or prior use of an NNRTI~* Certain PI mutations~* Hepatitis B infection within 90 days prior to study entry~* Certain therapies or medications within 30 days prior to study entry~* Heartbeat abnormalities or symptoms potentially related to heart block, such as unexplained fainting, dizziness, or palpitations, occurring within 180 days prior to study entry~* Drug or alcohol use or dependence that would interfere with adherence to the study requirements~* Serious illness requiring systemic treatment or hospitalization until the participant either completes therapy or has been clinically stable on therapy for at least 14 days prior to study entry~* Allergy or sensitivity to study medications or their formulations~* Current involuntarily incarceration for treatment of either a mental or physical illness~* Treatment for an active AIDS-defining opportunistic infection within 30 days prior to screening~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An fMRI Study of Opioid-related Changes in Neural Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* good health~* between the ages of 18 and 35,~* fluent in English~* right-handed (for the fMRI scan)~Exclusion Criteria:~* Self-reported current or past diagnoses of physical or mental illness.~* Score on the Patient Health Questionnaire (depressive symptoms) above a 13~* Positive urine drug test (for Tetrahydrocannabinol (THC), Opiates, Cocaine, Amphetamine (AMP), and Methamphetamine (mAMP))~* Positive urine pregnancy test~* Use of any prescription medication, except for birth control~* Use of any over-the-counter medications on the day of the fMRI session and 24 hours after the fMRI session~* Self-reported problems with liver functioning, including hepatitis or liver failure~* Difficulty swallowing or taking pills~* BMI greater than 35 or weight greater than 400 lbs~* Claustrophobia~* Nonremovable metal in the body

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- naltrexone (Type: EXPERIMENTAL): single 50mg dose of naltrexone
- sugar pill (Type: PLACEBO_COMPARATOR): single sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have chronic renal insufficiency (pre-dialysis)~* Have below normal creatinine clearance~* Have elevated parathyroid hormone levels~Exclusion Criteria:~* Pregnant or nursing~* Heart attack in the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cinacalcet (AMG 073) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Screening laboratory result indicating hepatitis C virus (HCV) GT5 or 6 infection.~* Participant has a positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid (RNA) greater than or equal to 1000 IU/mL at Screening Visit.~* Participant must be HCV treatment-naïve (i.e., has never received a single dose of any approved or investigational anti-HCV medication) or treatment-experienced (i.e., has failed prior interferon \[IFN\] or pegylated interferon \[pegIFN\] with or without ribavirin \[RBV\], or sofosbuvir \[SOF\] plus RBV with or without pegIFN therapy). Prior HCV treatment with any other approved or investigational medications is not allowed. Previous HCV treatment must have been completed greater than or equal to 2 months prior to screening.~* Participant must be documented as having no cirrhosis or compensated cirrhosis.~Exclusion Criteria:~* Female participant who is pregnant, breastfeeding, or is considering becoming pregnant during the study or for approximately 30 days after the last dose of study drug.~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.~* Positive test result at screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).~* HCV genotype performed during screening indicating co-infection with more than one HCV genotype.~* History of severe, life-threatening or other significant sensitivity to any excipients of the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glecaprevir/Pibrentasvir for 8 Weeks (Type: EXPERIMENTAL): Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.
- Glecaprevir/Pibrentasvir for 12 Weeks (Type: EXPERIMENTAL): Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven classical HL~* First diagnosis, no previous treatment~* Age: 18-60 years~* Stage I, IIA with risk factors a-d, IIB with RF c-d:~  1. large mediastinal mass~ 2. extranodal lesions~ 3. elevated ESR~ 4. ≥ 3 nodal areas confirmed by central review.~Exclusion Criteria:~* Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)~* History of other malignancy ≤ 5 years~* Prior chemotherapy or radiation therapy~* Concurrent disease precluding protocol treatment~* Pregnancy, lactation~* Non-compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): 4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
- Arm B (Type: EXPERIMENTAL): 4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be between 6 and 12 years of age inclusive, have a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) as defined by the DSM-IV established through clinical interview by the investigator and corroborated by the SNAP-IV parent rating scale, who in the opinion of the parents/caregivers exhibit significant after-school/evening behavioural difficulties where 12 hour coverage is desired~* Eligible patients will be evaluated after a minimum 3 day washout period without ADHD medication~* In addition, patients must also have a CGI-Severity score, at baseline of moderate, marked, severe or extremely severe in order to be eligible~* Patients could have had no prior treatment for ADHD or are presently taking something or could have had ADHD medication treatment in the past~Exclusion Criteria:~* No patients with marked anxiety, tension, aggression or agitation, glaucoma, an ongoing seizure disorder, a psychotic disorder, a diagnosis of Tourette's disorder, or a family history of Tourette's disorder, bipolar disorder, suspected mental retardation, significant learning disability, eating disorder or history of one, pre-existing gastrointestinal narrowing~* No patient with inability to swallow the medication whole, those with any unstable medical illness were excluded

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurogenic Inflammation in Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes with and without polyneuropathy.~* Patients with type 2 diabetes with a history of Charcot's disease.~* Healthy controls.~* Signed informed consent.~Exclusion Criteria:~* Peripheral arterial disease: toe pressure \< 70 mm Hg and/or transcutaneous oxygen tension \< 40 mm Hg and/or claudication.~* Renal insufficiency: MDRD creatinin clearance \< 30 ml/min.~* Systemic disease such as vasculitis or rheumatoid arthritis.~* Malignancy.~* (Diabetic) foot ulcer.~* Gout.~* Bacterial infection of an extremity.~* Skin condition of the dorsal aspect of the foot or the medial side of the upper arm.~* Bleeding disorder such as hemophilia.~* Use of medication for asthma.~* Impaired immunity such as in HIV/AIDS.~* Capillary blood glucose \< 3 mmol/l or \> 20 mmol/l at the time of the study.~* Peripheral oedema.~* Vaccination in the two months prior to study inclusion.~* Chemotherapy or radiation therapy in the twelve months prior to study inclusion.~* Surgery in the two months prior to study inclusion.~* Previous adverse reaction to Candida albicans antigen.~* Acute infection at the time of the study or in the month prior to study inclusion.~* Transfusion in the two months prior to study inclusion.~* Use of immunosuppressants in the two months prior to study inclusion.~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Healthy controls (Type: EXPERIMENTAL): None
- Diabetes (Type: EXPERIMENTAL): Patients with diabetes mellitus without polyneuropathy.
- Polyneuropathy (Type: EXPERIMENTAL): Patients with diabetes and polyneuropathy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 20 and 65 who have undergone thyroidectomy due to thyroid cancer and of American Society of Anesthesiologists (ASA) Physical Status Class 1 or Class 2~Exclusion Criteria:~* Patients experiencing pain for any cause or taking an analgesic~* Pregnant patients~* Patients with severe heart, kidney, or liver disease~* Patients with a psychiatric or neurological disorder~* Patients with a contraindication or allergic response to lidocaine~* Patients with a contraindication or allergic response to magnesium

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- The effect of perioperative lidocaine infusion (Type: EXPERIMENTAL): None
- The effect of perioperative magnesium infusion (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of chronic low back pain; chronic pain defined as pain lasting for at least 3 months.~* Subject's pain must require a strong analgesic (defined as World Health Organization (WHO) step III) as judged by the investigator.~* The painDETECT diagnostic screening questionnaire score must be:~  * positive or~ * unclear.or If the subject is being treated with a stable regimen of centrally acting analgesics (opioids) and/or co-analgesics, even a negative painDETECT score (but of at least 9) at the enrollment visit will be acceptable.~* If under regular daily pretreatment with a WHO step II/step III opioid analgesic and/or a centrally acting co-analgesic:~  * Subjects must be taking a WHO step II or step III analgesic or co- analgesic on a daily basis for at least 2 weeks prior to the enrollment visit.~ * Subjects pretreated with a WHO step II opioid analgesic and/or a centrally acting co-analgesic must have reported an average pain intensity score of at least 5 points (NRS-3≥5) during the last 3 days prior to the enrollment visit. or If under regular, daily pretreatment with a WHO step I analgesic monotherapy or if no regular analgesic pretreatment is reported:~ * Subjects must have an average pain intensity score of at least 6 points NRS-3≥6) in the last 3 days prior to the enrollment visit.~Exclusion Criteria:~* Presence of concomitant painful conditions other than low back pain that could confound the subject's trial assessments or self-evaluation of the index pain, e.g., syndromes with widespread pain such as fibromyalgia.~* Low back pain caused by cancer and/or metastatic diseases.~* Any painful procedures planned during the trial period (e.g., major surgery) that may, in the opinion of the investigator, affect the effectiveness or safety assessments of the Investigational Medicinal Product (IMP).~* Pending litigation or application for insurance/governmental benefits due to chronic pain or disability and, if granted, benefits might be influenced by a successful participation in the trial.~* Rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, lactose intolerance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tapentadol Prolonged Release (Type: EXPERIMENTAL): Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
- Tapentadol Prolonged Release with Pregabalin (Type: ACTIVE_COMPARATOR): Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with age of 20-75 years old (inclusive) in Taiwan of both genders~* Out-patients who had been diagnosed as non-erosive gastroesophageal reflux disease (NERD)~* Patients with heartburn or regurgitation (either one) as main symptom at least 2 days a week and had been present for \> or = 1 month before screening~* Patients with heartburn or regurgitation (either one) during the 7 days screening period, either with frequency for \> or = 4 days of mild symptom, or for \> or = 2 days of moderate to severe symptom~* Patients have signed the informed consent form~Exclusion Criteria:~* Patients with erosive gastroesophageal reflux disease (GERD), Barrett's esophagus or esophageal stricture~* Patients with active or healing gastroduodenal ulcer (except scars)~* Patients with history of gastric, duodenal or esophageal surgery~* Patients with malignant disease of any kind~* Patients with intrahepatic stone, gallstone, gallbladder sludge, hepatic or pancreatic carcinoma as evidenced by abdominal ultrasonography~* Patients with ischemic heart disease as evidenced by electrocardiogram~* Female patients who are pregnant or nursing mother~* Patients with a history of allergy to any of the study drugs or their related compounds~* Patients with a history of alcohol or drug abuse~* Patients with clinically significant liver disease (aspartate aminotransferase (AST), alanine aminotransferase (ALT)\>2 upper limits of normal)~* Patients with clinically significant renal disease (serum creatinine \>1.5 mg/dl)~* Patients taken a proton pump inhibitor (PPI) within 14 days before screening, or a H2-blocker, prokinetic agent or antacid within 7 days before screening~* Patients participated any investigational drug trial within 4 weeks before screening~* Patients with any other conditions or diseases that investigator considers it is not appropriate to enter the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sodium alginate (Type: EXPERIMENTAL): Oral suspension, 50 mg/ml
- Omeprazole (Type: ACTIVE_COMPARATOR): 20 mg/cap

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C levels above those recommended by the National Cholesterol Education~* Program Adult Treatment Panel III (NCEP-ATP III) based on each patient risk factors following a 3-month period of lifestyle changes.~Exclusion Criteria:~* Triglycerides \>500 mg/dL, renal disease (serum creatinine levels \>1.6 mg/dL), hypothyroidism \[thyroid stimulating hormone (TSH) \>5 IU/mL\] and liver disease (ALT and/or AST levels \>3-fold upper limit of normal in 2 consecutive measurements).~* Patients with hypertension will be included in the study if they are on stable medication for at least 3 months and their blood pressure is adequately controlled (no change in their treatment will be made during the study period).~* Patients currently taking lipid lowering drugs or having stopped them less than 4 weeks before study entry will be excluded

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin 40 mg (Type: ACTIVE_COMPARATOR): All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
- Simvastatin 10 mg plus ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent~* Mentally stable and able to comply with the procedures of the study protocol~* Clinical history compatible with type 1 diabetes diagnosed less than 10 days of enrolment Stimulate c-peptide \>0.1 nmol/l~Exclusion Criteria:~* Patients with BMI\>30~* Patients with unstable cardiovascular status~* Patients with active infections, unless treatment is not judged necessary by the investigators~* Patients with serological evidence of infection with HIV, hepatitis B or hepatitis C.~* Sexually active females who are not a) postmenopausal, b) surgically sterile or c) using an acceptable method of contraception: oral contraceptives, Norplant, Depo-provera and barrier devices combined with spermicidal gel are acceptable.~* Patients with known or previous malignancy. Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with autologous MSC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cells (Type: ACTIVE_COMPARATOR): Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete